Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs

Current Topics in Medicinal Chemistry

Volumn 10, Issue 17, 2010, Pages 1799-1809

  Syvänen, Stina ^a,b   Hammarlund Udenaes, Margareta ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Active transport; Blood brain barrier; Drug interactions; Efflux pumps; P glycoprotein; PET; Pharmacokinetics; Study design

Indexed keywords

2 DIPROPYLAMINO 1,2,3,4 TETRAHYDRO 6 (4 METHOXYPHENYLSULFONYLMETHYL)NAPHTHALENE; ALTANSERIN; CARAZOLOL; CARBON 11; CYCLOSPORIN A; ELACRIDAR; FLUORINE 18; FLUOROCARAZOLOL; GLYCOPROTEIN P; LANIQUIDAR; LOPERAMIDE; MC 18; NORLOPERAMIDE; TARIQUIDAR; TRACER; UNCLASSIFIED DRUG; VERAPAMIL; VOFOPITANT;

ACTIVE TRANSPORT; ARTICLE; DRUG DISPOSITION; DRUG DISTRIBUTION; HUMAN; NONHUMAN; PARTITION COEFFICIENT; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SPECIES DIFFERENCE;

ANIMALS; BINDING SITES; BRAIN DISEASES; CARBON RADIOISOTOPES; HUMANS; LOPERAMIDE; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; VERAPAMIL;

EID: 77957998294     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610792927997     Document Type: Article

References (66)

1. Choo E.F.; Leake B.; Wandel C.; Imamura H.; Wood A.J.; Wilkinson G.R.; Kim R.B. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 prote-ase inhibitors into brain and testes. Drug Metab. Dispos., 2000, 28, 655-660.
2. Kaddoumi A.; Choi S.U.; Kinman L.; Whittington D.; Tsai C.C.; Ho R.J.; Anderson B.D.; Unadkat J.D. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid. Drug Metab. Dispos., 2007, 35, 1459-1462.
3. Chen C.; Hanson E.; Watson J.W.; Lee J.S. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab. Dispos., 2003, 31, 312-318.
4. Mahar Doan K.M.; Wring S.A.; Shampine L.J.; Jordan K.H.; Bishop J.P.; Kratz J.; Yang E.; Serabjit-Singh C.J.; Adkison K.K.; Polli J.W. Steady-state brain concentrations of antihis-tamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding. Pharmacology, 2004, 72, 92-98.
5. Hammarlund-Udenaes M.; Friden M.; Syvänen S.; Gupta A. On the rate and extent of drug delivery to the brain. Pharm Res., 2008, 25, 1737-1750.
6. Jeffrey P.; Summerfield S. Assessment of the blood-brain barrier in CNS drug discovery. Neurobiol. Dis., 2009, 37, 33-37.
7. Watson J.; Wright S.; Lucas A.; Clarke K.L.; Viggers J.; Cheetham S.; Jeffrey P.; Porter R.; Read K.D. Receptor occu-pancy and brain free fraction. Drug Metab. Dispos., 2009, 37, 753-760.
8. Matsson P.; Pedersen J.M.; Norinder U.; Bergstrom C.A.; Artursson P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res., 2009, 26, 1816-1831.
9. Balayssac D.; Authier N.; Cayre A. Comment regarding Bergmann et al.'s Assessment of the in vitro and in vivo properties of a 99mTc-labeled inhibitor of the multidrug resistant gene product of P-glycoprotein. Nucl Med. Biol., 2003, 30, 455.
10. Innis R.B.; Cunningham V.J.; Delforge J.; Fujita M.; Gjedde A.; Gunn R.N.; Holden J.; Houle S.; Huang S.C.; Ichise M.; Iida H.; Ito H.; Kimura Y.; Koeppe R.A.; Knudsen G.M.; Knuuti J.; Lammertsma A.A.; Laruelle M.; Logan J.; Maguire R.P.; Mintun M.A.; Morris E.D.; Parsey R.; Price J.C.; Slifstein M.; Sossi V.; Suhara T.; Votaw J.R.; Wong D.F.; Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab., 2007, 27, 1533-1539.
11. Summerfield S.G.; Lucas A.J.; Porter R.A.; Jeffrey P.; Gunn R.N.; Read K.R.; Stevens A.J.; Metcalf A.C.; Osuna M.C.; Kilford P.J.; Passchier J.; Ruffo A.D. Toward an improved prediction of human in vivo brain penetration. Xenobiotica, 2008, 38, 1518-1535.
12. Gupta A.; Chatelain P.; Massingham R.; Jonsson E.N.; Hammarlund-Udenaes M. Brain distribution of cetirizine enantiomers: comparison of three different tissue-to-plasma partition coefficients: K(p), K(p,u), and K(p,uu). Drug Metab. Dispos., 2006, 34, 318-323.
13. Syvänen S.; Xie R.; Sahin S.; Hammarlund-Udenaes M. Pharmacoki-netic consequences of active drug efflux at the blood-brain barrier. Pharm. Res., 2006, 23, 705-717.
14. Wang Y.; Welty D.F. The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a mi-crodialysis-pharmacokinetic approach. Pharm. Res., 1996, 13, 398-403.
15. Kalvass J.C.; Maurer T.S. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm. Drug Dispos., 2002, 23, 327-338.
16. Mano Y.; Higuchi S.; Kamimura H. Investigation of the high partition of YM992, a novel antidepressant, in rat brain - in vitro and in vivo evidence for the high binding in brain and the high permeability at the BBB. Biopharm. Drug Dispos., 2002, 23, 351-360.
17. Nicholson C.; Phillips J.M. Ion diffusion modified by tortuosity and volume fraction in the extracellular microenvironment of the rat cere-bellum. J. Physiol., 1981, 321, 225-257.
18. Gunn R.N.; Gunn S.R.; Cunningham V.J. Positron emission tomo-graphy compartmental models. J. Cereb. Blood Flow Metab., 2001, 21, 635-652.
19. Carson R.E.; Channing M.A.; Blasberg R.G.; Dunn B.B.; Cohen R.M.; Rice K.C.; Herscovitch P. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J. Cereb. Blood Flow Metab., 1993, 13, 24-42.
20. Logan J.; Fowler J.S.; Volkow N.D.; Wolf A.P.; Dewey S.L.; Schlyer D.J.; MacGregor R.R.; Hitzemann R.; Bendriem B.; Gatley S.J. Graphical analysis of reversible radioligand binding from time activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab., 1990, 10, 740-747.
21. Todd M.M.; Weeks J.B.; Warner D.S. Cerebral blood flow, blood volume, and brain tissue hematocrit during isovolemic hemodilution with hetastarch in rats. Am. J. Physiol., 1992, 263, H75-82.
22. Gjedde A.; Christensen O. Estimates of Michaelis-Menten constants for the two membranes of the brain endothelium. J. Cereb. Blood Flow Metab., 1984, 4, 241-249.
23. Pardridge W.M.; Triguero D.; Yang J.; Cancilla P.A. Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. J. Pharmacol. Exp. Ther., 1990, 253, 884-891.
24. Friden M.; Winiwarter S.; Jerndal G.; Bengtsson O.; Wan H.; Bred-berg U.; Hammarlund-Udenaes M.; Antonsson M. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J. Med. Chem., 2009, 52, 6233-6243.
25. Luurtsema G.; Molthoff C.F.; Schuit R.C.; Windhorst A.D.; Lammertsma A.A.; Franssen E.J. Evaluation of (R)- [11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl. Med. Biol., 2005, 32, 87-93.
26. Lubberink M.; Luurtsema G.; van Berckel B.N.; Boellaard R.; Toornvliet R.; Windhorst A.D.; Franssen E.J.; Lammertsma A.A. Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. J. Cereb. Blood Flow Metab., 2007, 27, 424-433.
27. Pauli-Magnus C.; von Richter O.; Burk O.; Ziegler A.; Mettang T.; Eichelbaum M.; Fromm M.F. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J. Pharmacol. Exp. Ther., 2000, 293, 376-382.
28. Verbeek J.; Windhorst A.D.; Schuit R.C.; Eriksson J.; Syvänen S.; Lammertsma A.A.; Luurtsema G. In: Synthesis and biological evaluation of [11C]D617: A metabolite of [11C]verapamil., 18th International Symposium on Radiopharmaceutical Chemistry (ISRC); S.o.R. Sciences: Edmonton, Canada, 2009.
29. Zoghbi S.S.; Liow J.S.; Yasuno F.; Hong J.; Tuan E.; Lazarova N.; Gladding R.L.; Pike V.W.; Innis R.B. 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain perme-ability-glycoprotein efflux. J. Nucl. Med., 2008, 49, 649-656.
30. Lazarova N.; Zoghbi S.S.; Hong J.; Seneca N.; Tuan E.; Gladding R.L.; Liow J.S.; Taku A.; Innis R.B.; Pike V.W. Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J. Med. Chem., 2008, 51, 6034-6043.
31. Seneca N.; Zoghbi S.S.; Liow J.S.; Kreisl W.; Herscovitch P.; Jenko K.; Gladding R.L.; Taku A.; Pike V.W.; Innis R.B. Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein. J. Nucl. Med., 2009, 50, 807-813.
32. Löscher W.; Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharmacol. Exp. Ther., 2002, 301, 7-14.
33. Langer O.; Bauer M.; Hammers A.; Karch R.; Pataraia E.; Koepp M.J.; Abrahim A.; Luurtsema G.; Brunner M.; Sunder-Plassmann R.; Zimprich F.; Joukhadar C.; Gentzsch S.; Dudczak R.; Kletter K.; Muller M.; Baumgartner C. Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R- [(11)C]verapamil. Epilepsia, 2007, 48, 1774-1784.
34. Kortekaas R.; Leenders K.L.; van Oostrom J.C.; Vaalburg W.; Bart J.; Willemsen A.T.; Hendrikse N.H. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol., 2005, 57, 176-179.
35. Toornvliet R.; van Berckel B.N.; Luurtsema G.; Lubberink M.; Geldof A.A.; Bosch T.M.; Oerlemans R.; Lammertsma A.A.; Franssen E.J. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin. Pharmacol, Ther., 2006, 79, 540-548.
36. Bartels A.L.; van Berckel B.N.; Lubberink M.; Luurtsema G.; Lammertsma A.A.; Leenders K.L. Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. Parkinsonism Relat. Disord., 2008, 14, 505-508.
37. Bauer M.; Karch R.; Neumann F.; Abrahim A.; Wagner C.C.; Kletter K.; Muller M.; Zeitlinger M.; Langer O. Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. Eur. J. Clin. Pharmacol., 2009, 65, 941-946.
38. Wagner C.C.; Bauer M.; Karch R.; Feurstein T.; Kopp S.; Chiba P.; Kletter K.; Löscher W.; Muller M.; Zeitlinger M.; Langer O. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C- verapamil and PET. J. Nucl. Med., 2009, 50, 1954-1961.
39. Dörner B.; Kuntner C.; Bankstahl J.P.; Bankstahl M.; Stanek J.; Wanek T.; Stundner G.; Mairinger S.; Löscher W.; Muller M.; Langer O.; Erker T. Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J. Med. Chem., 2009, 52, 6073-6082.
40. Luurtsema G.; Schuit R.C.; Klok R.P.; Verbeek J.; Leysen J.E.; Lammertsma A.A.; Windhorst A.D. Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and bio-distribution in rats. Nucl. Med. Biol., 2009, 36, 643-649.
41. van Waarde A.; Ramakrishnan N.K.; Rybczynska A.A.; Elsinga P.H.; Berardi F.; de Jong J.R.; Kwizera C.; Perrone R.; Cantore M.; Sijbesma J.W.; Dierckx R.A.; Colabufo N.A. Synthesis and preclinical evaluation of novel PET probes for P-glycoprotein function and ex-pression. J. Med. Chem., 2009, 52, 4524-4532.
42. de Vries E.F.; Kortekaas R.; van Waarde A.; Dijkstra D.; Elsinga P.H.; Vaalburg W. Synthesis and evaluation of dopamine D3 receptor antagonist 11C-GR218231 as PET tracer for P-glycoprotein. J. Nucl. Med., 2005, 46, 1384-1392.
43. Doze P.; Van Waarde A.; Elsinga P.H.; Hendrikse N.H.; Vaalburg W. Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood-brain barrier. Synapse, 2000, 36, 66-74.
44. Bart J.; Dijkers E.C.; Wegman T.D.; de Vries E.G.; van der Graaf W.T.; Groen H.J.; Vaalburg W.; Willemsen A.T.; Hendrikse N.H. New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics. Br. J. Pharmacol., 2005, 145, 1045-1051.
45. Syvänen S.; Lindhe O.; Palner M.; Kornum B.R.; Rahman O.; Långström B.; Knudsen G.M.; Hammarlund-Udenaes M. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab. Dispos., 2009, 37, 635-643.
46. la Fougere C.; Boning G.; Bartmann H.; Wangler B.; Nowak S.; Just T.; Wagner E.; Winter P.; Rominger A.; Forster S.; Gildehaus F.J.; Rosa-Neto P.; Minuzzi L.; Bartenstein P.; Potschka H.; Cumming P. Uptake and binding of the serotonin 5-HT(1A) antagonist [(18)F]- MPPF in brain of rats: Effects of the novel P-glycoprotein inhibitor tariquidar. Neuroimage, 2009, 28, 28.
47. Passchier J.; van Waarde A.; Doze P.; Elsinga P.H.; Vaalburg W. Influence of P-glycoprotein on brain uptake of [18F]MPPF in rats. Eur. J. Pharmacol., 2000, 407, 273-280.
48. Passchier J.; van Waarde A.; Pieterman R.M.; Elsinga P.H.; Pruim J.; Hendrikse H.N.; Willemsen A.T.; Vaalburg W. In vivo delineation of 5-HT1A receptors in human brain with [18F]MPPF. J. Nucl. Med., 2000, 41, 1830-1835.
49. Liow J.S.; Lu S.; McCarron J.A.; Hong J.; Musachio J.L.; Pike V.W.; Innis R.B.; Zoghbi S.S. Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5- HT1A receptor radioligand, [11C](R)-(-)-RWAY. Synapse, 2007, 61, 96-105.
50. Yasuno F.; Zoghbi S.S.; McCarron J.A.; Hong J.; Ichise M.; Brown A.K.; Gladding R.L.; Bacher J.D.; Pike V.W.; Innis R.B. Quantification of serotonin 5-HT1A receptors in monkey brain with [11C](R)-(-)-RWAY. Synapse, 2006, 60, 510-520.
51. Zhang X.Y.; Yasuno F.; Zoghbi S.S.; Liow J.S.; Hong J.; McCarron J.A.; Pike V.W.; Innis R.B. Quantification of serotonin 5-HT1A receptors in humans with [11C](R)-(-)-RWAY: radiometabolite(s) likely confound brain measurements. Synapse, 2007, 61, 469-477.
52. Hendrikse N.H.; de Vries E.G.; Eriks-Fluks L.; van der Graaf W.T.; Hospers G.A.; Willemsen A.T.; Vaalburg W.; Franssen E.J. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res., 1999, 59, 2411-2416.
53. 11C]verapamil measured with PET. Neuroimage, 2003, 20, 1775-1782.
54. Syvänen S.; Blomquist G.; Sprycha M.; Höglund A.U.; Roman M.; Eriksson O.; Hammarlund-Udenaes M.; Långström B.; Bergström M. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Neuroimage, 2006, 32, 1134-1141.
55. Eriksson O.; Josephsson R.; Långström B.; Bergström M. Positron emission tomography and target-controlled infusion for precise modulation of brain drug concentration. Nucl. Med. Biol., 2008, 35, 299-303.
56. Eriksson O.; Wallberg A.; Syvänen S.; Josephsson R.; Långström B.; Bergström M. A computerized infusion pump for control of tissue tracer concentration during positron emission tomography in vivo pharmacokinetic/pharmacodynamic measurements. BMC Med. Phys., 2008, 8, 2.
57. Syvänen S.; Hooker A.; Rahman O.; Wilking H.; Blomquist G.; Långström B.; Bergström M.; Hammarlund-Udenaes M. Pharma-cokinetics of P-glycoprotein inhibition in the rat blood-brain barrier. J. Pharm. Sci., 2008, 97, 5386-5400.
58. Hsiao P.; Sasongko L.; Link J.M.; Mankoff D.A.; Muzi M.; Collier A.C.; Unadkat J.D. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. J. Pharmacol. Exp. Ther., 2006, 317, 704-710.
59. Xie R.; Bouw M.R.; Hammarlund-Udenaes M. Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecidsensitive transport. Br. J. Pharmacol., 2000, 131, 1784-1792.
60. Friden M.; Gupta A.; Antonsson M.; Bredberg U.; Hammarlund-Udenaes M. In vitro methods for estimating unbound drug con-centrations in the brain interstitial and intracellular fluids. Drug Metab. Dispos, 2007, 35, 1711-1719.
61. Friden M.; Ljungqvist H.; Middleton B.; Bredberg U.; Hammar-lund-Udenaes M. Improved measurement of drug exposure in the brain using drug-specific correction for residual blood. J. Cereb. Blood Flow Metab., 2009.
62. Okamura T.; Kikuchi T.; Okada M.; Toramatsu C.; Fukushi K.; Takei M.; Irie T. Noninvasive and quantitative assessment of the function of multidrug resistance-associated protein 1 in the living brain. J. Cereb. Blood Flow Metab., 2009, 29, 504-511.
63. Lee Y.J.; Maeda J.; Kusuhara H.; Okauchi T.; Inaji M.; Nagai Y.; Obayashi S.; Nakao R.; Suzuki K.; Sugiyama Y.; Suhara T. In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil. J. Pharmacol. Exp. Ther., 2006, 316, 647-653.
64. Sasongko L.; Link J.M.; Muzi M.; Mankoff D.A.; Yang X.; Collier A.C.; Shoner S.C.; Unadkat J.D. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomo-graphy. Clin. Pharmacol. Ther., 2005, 77, 503-514.
65. Kuntner C.; Bankstahl J.P.; Bankstahl M.; Stanek J.; Wanek T.; Stundner G.; Karch R.; Brauner R.; Meier M.; Ding X.; Muller M.; Löscher W.; Langer O. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur. J. Nucl. Med. Mol. Imaging, 2009, 17, 17.
66. Syvänen S.; Luurtsema G.; Molthoff C.F.; Windhorst A.D.; Huisman M.C.; Lammertsma A.A.; Voskuyl R.A.; de Lange C.M. In: P-glycoprotein function in the blood-brain barrier of epileptic rats, IXth International Conference on Quantification of Brain Function with PET; I.S.f.C.B.F. Metabolism: Chicago, US, 2009.